Best Oncology journal

Treatment of Early-Stage Hormone Receptor–Positive Breast Cancer

Hope S. Rugo, MD

H&O  What are the most important questions for oncologists treating patients with early-stage hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer after surgery? HR  […]

From Recent Issues

Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma Is Ready for Prime Time 

  Abstract: The significant advances made in the treatment of multiple myeloma (MM) have allowed for a paradigm shift away from the early use of high-dose […]

How Biosimilars Will Impact Costs and Care in Oncology

  H&O  How does a biosimilar compare to a biologic therapy or a generic formulation? GL To start, it is necessary to distinguish biologic molecules from […]

Phosphoinositide 3-Kinase Inhibition in the Treatment of Hormone Receptor–Positive Breast Cancer

  H&O  Which patients are eligible for treatment with alpelisib?  HR  One of the major advances this year in treating hormone receptor (HR)-positive breast cancer has […]


Highlights From the XVIII International Workshop on Chronic Lymphocytic Leukemia

A Review of Selected Presentations From the XVIII iwCLL • September 20-23, 2019 • Edinburgh, Scotland Ibrutinib Versus Placebo in Patients With Asymptomatic, Treatment-Naive Early-Stage Chronic […]

A New Strategy for Uncontrollable Bleeding After Treatment With Rivaroxaban or Apixaban

Abstract: Anticoagulants are used in several settings to reduce the risk of thromboembolic events, but they can be associated with severe complications, such as potentially fatal bleeding. […]

Highlights in Lymphoma From the 2019 American Society of Clinical Oncology Annual Meeting

A Review of Selected Presentations From the 2019 ASCO Annual Meeting • May 31-June 4, 2019 • Chicago, Illinois Brentuximab Vedotin With Chemotherapy for Stage 3/4 […]